[Edaily Reporter Kim Hyung-il ] Newintec ( NUIN TEK CO., LTD(012340)) announced on the 10th that CEO Jang Ki-soo has been steadily increasing his stake in the company, demonstrating his commitment to medium- to long-term growth.
NUIN TEK CO., LTD CI. (Photo = NUIN TEK CO., LTD)
Jang Ki-soo, CEO of NUIN TEK CO., LTD, purchased 217,613 shares of NUIN TEK CO., LTD stock on the open market. As a result, CEO Jang’s holdings of NUIN TEK CO., LTD stock increased to 7,104,535 shares, expanding his stake to 32.23%.
CEO Jang had previously participated as the sole investor in a 3 billion won third-party private placement conducted by NUIN TEK CO., LTD last July. At that time, he acquired 3,344,481 common shares at 897 won per share and completed the payment.
CEO Jang continued to expand his stake by purchasing additional shares following his participation in the capital increase. NUIN TEK CO., LTD plans to enhance its corporate value by improving core business performance and expanding high-value-added products and new business ventures.
NUIN TEK CO., LTD. official stated, “The CEO’s participation in the capital increase and these on-market purchases demonstrate his commitment to the company’s mid- to long-term growth and corporate value,” adding, “We will build on the trend of improved performance in the first half of the year and drive sustained growth by expanding sales of high-value-added products and new business ventures.”
(Photo: Blind)
One of the concerns facing the Lee Jae-myung administration is the decline in support among young people. According to Gallup Korea’s presidential job approval ratings, the approval…
The KRX Health Care Index rose 4.53% from the previous session on Oct. 1, signaling a rare tailwind for South Korea’s pharmaceutical and biotech sector. Among the gainers, GIInnovation and G2GBio drew…
(Graphic: ChatGPT)
“While existing ex vivo chimeric antigen receptor T-cell (CAR-T) therapies are personalized treatments that require cell collection from each patient for manufacturing, the in v…
